{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:41:54Z","timestamp":1694940114557},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate whether 3\u2010hydroxy\u20103\u2010methylglutaryl\u2010coenzyme A reductase inhibitor (statin) use is associated with an increased risk of diabetes mellitus and hyperglycemia, we performed a nested case\u2010control study using a postmarketing surveillance database in Japan. The database cohort included 26,849 cases of statin use and 5308 cases of other lipid\u2010lowering drug use in patients with hyperlipidemia. Participants received at least 1 type of statin, had a clear medication history of statin use, and had no complications of diabetes mellitus. Cases were defined as onset of diabetes mellitus or hyperglycemia during statin intake. For each case, 20 controls were randomly selected and matched by time point. The factors associated with an increased risk of diabetes mellitus and hyperglycemia during statin intake examined included sex, age, body mass index, statin use duration, complications, concomitant medication, and clinical laboratory tests. Statin\u2010associated diabetes mellitus or hyperglycemia was identified based on abnormal elevation of blood glucose concentrations beyond the reference range. A total of 19,868 patients met the inclusion criteria, of whom 24 were patients in the case group. Two complicating factors, fatty liver (adjusted odds ratio 16.10) and hyperuricemia (adjusted odds ratio 28.96), were extracted for onset of diabetes mellitus or hyperglycemia. Nonalcoholic fatty liver was associated with diabetes mellitus, obesity, and insulin resistance, and hyperuricemia was associated with lifestyle. This study suggested that the onset of diabetes mellitus or hyperglycemia might be increased with statin use in patients with complications of fatty liver and hyperuricemia.<\/jats:p>","DOI":"10.1002\/cpdd.444","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T19:55:10Z","timestamp":1519242910000},"page":"800-810","source":"Crossref","is-referenced-by-count":1,"title":["Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG\u2010CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan"],"prefix":"10.1002","volume":"7","author":[{"given":"Masayuki","family":"Hashiguchi","sequence":"first","affiliation":[{"name":"Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy Keio University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy Keio University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikiko","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Hygienic Chemistry, Faculty of Pharmacy Keio University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy Keio University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Shiga","sequence":"additional","affiliation":[{"name":"Department of Cardiology Tokyo Women's Medical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel) final report","volume":"106","author":"National Cholesterol Education Program (NCEP)","year":"2002","journal-title":"Circulation"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133317.49796.0E"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0738"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"e_1_2_11_6_1","unstructured":"US Food and Drug Administration.FDA drug safety communication: important safety label changes to cholesterol\u2010lowering statin drugs.2012.http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm293101.htm. Accessed August 1 2017."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.860"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-015935"},{"key":"e_1_2_11_9_1","first-page":"855","article-title":"Indispensable large\u2010scale databases in pharmacovigilance","volume":"223","author":"Fujita T","year":"2007","journal-title":"J Clin Exp Med"},{"issue":"4","key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/JCP.0000000000000367","article-title":"The pharmacovigilance syndrome","volume":"35","author":"Greenblatt DJ","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80007-6"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e318262316f"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199309030-00008"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2003.00456.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02527.x"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0225-0"},{"key":"e_1_2_11_18_1","unstructured":"JSPE Pharmacoepidemiology & Database Task Force (PE&DB TF).Survey of Japanese databases in Japan available for clinical\/pharmaco\u2010epidemiology. 2016.10.http:\/\/www.jspe.jp\/committee\/020\/0210\/. Accessed August 1 2017."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002040"},{"key":"e_1_2_11_20_1","first-page":"205","article-title":"A database of anti\u2010hypertensive drugs from drug use investigations and its practical use example","volume":"36","author":"Fujita T","year":"2007","journal-title":"Jpn J Stat Data Sci"},{"key":"e_1_2_11_21_1","unstructured":"Hyperglycaemia\/new onset diabetes mellitus (SMQ).Medical Dictionary for Regulatory Activities.http:\/\/bioportal.bioontology.org\/ontologies\/MEDDRA?p=classes&conceptid=20000041. Accessed December 11 2017."},{"key":"e_1_2_11_22_1","first-page":"902","article-title":"Appropriate body\u2010mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","journal-title":"Lancet"},{"key":"e_1_2_11_23_1","unstructured":"WHO.Obesity and overweight. Fact sheet. Updated October 2017. World Health Organization.http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/. Accessed December 11 2017."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.07.018"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0792"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0269-5"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0288"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt320"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.625"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.08.004"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04403.x"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067406"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2610"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3244"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T23:37:16Z","timestamp":1694907436000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1002\/cpdd.444"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.444","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]}}}